Global Blood Therapeutics, Inc.
Histone methyltransferase inhibitors
Last updated:
Abstract:
The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. ##STR00001## where R.sup.1, alk, R.sup.2, Z.sup.1, Z.sup.2, X, R.sup.3, R.sup.4, B, a, and b are as described herein.
Status:
Grant
Type:
Utility
Filling date:
21 Dec 2017
Issue date:
10 Nov 2020